Market closed
Aurinia Pharmaceuticals/$AUPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Ticker
$AUPH
Sector
Trading on
Industry
Biotechnology
Headquarters
Edmonton, Canada
Employees
130
Website
AUPH Metrics
BasicAdvanced
$1.1B
202.50
$0.04
1.27
-
Price and volume
Market cap
$1.1B
Beta
1.27
52-week high
$9.98
52-week low
$4.77
Average daily volume
1.3M
Financial strength
Current ratio
4.568
Quick ratio
4.046
Long term debt to equity
17.033
Total debt to equity
21.026
Interest coverage (TTM)
2.59%
Management effectiveness
Return on assets (TTM)
1.42%
Return on equity (TTM)
1.52%
Valuation
Price to earnings (TTM)
202.5
Price to revenue (TTM)
4.928
Price to book
3.02
Price to tangible book (TTM)
3.06
Price to free cash flow (TTM)
26.272
Growth
Revenue change (TTM)
33.97%
Earnings per share change (TTM)
-107.34%
3-year revenue growth (CAGR)
72.76%
3-year earnings per share growth (CAGR)
-69.42%
What the Analysts think about AUPH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
AUPH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AUPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AUPH News
AllArticlesVideos
Insiders Are Loading Up on These 4 Biotech Stocks Now
24/7 Wall Street·1 month ago
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations
Benzinga·2 months ago
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals (AUPH) has a market cap of $1.1B as of April 25, 2025.
What is the P/E ratio for Aurinia Pharmaceuticals stock?
The price to earnings (P/E) ratio for Aurinia Pharmaceuticals (AUPH) stock is 202.5 as of April 25, 2025.
Does Aurinia Pharmaceuticals stock pay dividends?
No, Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Aurinia Pharmaceuticals dividend payment date?
Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (AUPH) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.